A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). 2021 Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed February 4, 2021.
   Google Scholar
• Shirtcliffe P, Weatherall M, Marsh S, et al. COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007;30(2):232–239.
   PubMed Web of Science ®Google Scholar
• Telfar Barnard L, Zhang J. The impact of respiratory disease in New Zealand: 2018 update. Asthma and Respiratory Foundation New Zealand. 2018. Available from: https://s3-ap-southeast-2.amazonaws.com/assets.asthmafoundation.org.nz/images/NZ-Impact-Report-2018_FINAL.pdf. Accessed April 20, 2021.
   Google Scholar
• Milne RJ, Beasley R. Hospital admissions for chronic obstructive pulmonary disease in New Zealand. N Z Med J. 2015;128(1408):23–35.
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Health loss in New Zealand: a report from the New Zealand burden of diseases, injuries and risk factors study, 2006–2016. 2013. Available from: https://www.moh.govt.nz/notebook/nbbooks.nsf/0/F85C39E4495B9684CC257BD3006F6299/$file/health-loss-in-new-zealand-final.pdf. Accessed September 11, 2020.
   Google Scholar
• Yang IA, Brown JL, George J, et al. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. 2020. Available from: https://copdx.org.au/copd-x-plan/. Accessed April 20, 2021.
   Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 report). 2017. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed April 20, 2021.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
   PubMed Web of Science ®Google Scholar
• Booker C, Harris H, Leitch S, et al. Best practice: newly subsidised medicines for COPD. Best Pract J. 2016;(74):7–13.
   Google Scholar
• PHARMAC. Online pharmaceutical schedule - April 2021: community schedule, respiratory system and allergies. 2021. Available from: https://schedule.pharmac.govt.nz/ScheduleOnline.php?code=A28&edition=2021-04. Accessed April 23, 2021.
   Google Scholar
• Tikkanen R, Osborn R, Mossialos E, et al. International health care system profile. New Zealand. 2020. Available from: https://www.commonwealthfund.org/international-health-policy-center/countries/new-zealand. Accessed April 20, 2021.
   Google Scholar
• HealthStat Primary Health Care Intelligence. HealthStat general practice database. Available from: http://www.healthstat.co.nz/Login.aspx?ReturnUrl=%2fdefault.aspx. Accessed April 20, 2021.
   Google Scholar
• Clinical Practice Research Datalink. 2021. Available from: https://www.cprd.com/. Accessed March 25, 2021.
   Google Scholar
• NHS Digital. Hospital Episode Statistics (HES). 2020. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. Accessed April 20, 2021.
   Google Scholar
• American Hospital Directory. 2021. Available from: https://www.ahd.com/. Accessed March 25, 2021.
   Google Scholar
• MedicineInsight. 2021. Available from: https://www.nps.org.au/medicine-insight. Accessed March 25, 2021.
   Google Scholar
• Martin GS. The essential nature of healthcare databases in critical care medicine. Crit Care. 2008;12(5):176.
   PubMed Web of Science ®Google Scholar
• Asche CV, Leader L, Plauschinat P, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2012;7:201–209.
   PubMed Web of Science ®Google Scholar
• Make B, Dutro MP, Paulose-Ram R, et al. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:1–9.
   PubMed Web of Science ®Google Scholar
• Diette GB, Orr P, McCormack MC, et al. Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines? Popul Health Manag. 2010;13(1):21–26.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Hoogenveen RT, et al. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:435–444.
   PubMedGoogle Scholar
• Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203–223.
   PubMedGoogle Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Best Practice Advocacy Centre New Zealand (BPACnz). Diagnosis and management of COPD in Māori and Pacific peoples. Best Pract J. 2012;43:14–25.
   Google Scholar
• Quint JK, O’Leary C, Venerus A, et al. Prescribing pathways to triple therapy: a multi-country, retrospective observational study of adult patients with chronic obstructive pulmonary disease. Pulm Ther. 2020;6(2):333–350.
   PubMedGoogle Scholar
• Quint JK, Venerus A, O’Leary C, et al. Prescribing pathways to triple therapy: a retrospective observational study of adults with chronic obstructive pulmonary disease in the UK. Int J Chron Obstruct Pulmon Dis. 2020;15:3261–3271.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–838.
   PubMed Web of Science ®Google Scholar
• Street RL Jr., Gordon HS, Ward MM, et al. Patient participation in medical consultations: why some patients are more involved than others. Med Care. 2005;43(10):960–969.
   PubMed Web of Science ®Google Scholar
• Jones RC, Price D, Ryan D, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014;2(4):267–276.
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Price DB, Nordyke RJ, et al. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75–80.
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Laliberte F, et al. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10.
   PubMed Web of Science ®Google Scholar
• Khdour MR, Hawwa AF, Kidney JC, et al. Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD). Eur J Clin Pharmacol. 2012;68(10):1365–1373.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Spangenthal S, Zvarich M, et al. ELLIPTA versus DISKUS plus HandiHaler in COPD: a randomized, open-label, crossover study in a clinical trial setting. Chronic Obstr Pulm Dis. 2020;7(2):118–129.
   PubMed Web of Science ®Google Scholar
• Negewo NA, Gibson PG, Wark PA, et al. Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2929–2942.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed April 20, 2021.
   Google Scholar
• Hanania NA, Papi A, Anzueto A, et al. Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Res. 2020;6:2.
   Google Scholar
• Dummer J, Tumilty E, Hannah D, et al. Health care utilisation and health needs of people with severe COPD in the southern region of New Zealand: a retrospective case note review. COPD. 2020;17(2):136–142.
   PubMedGoogle Scholar
• Parkin L, Barson D, Zeng J, et al. Patterns of use of long-acting bronchodilators in patients with COPD: a nationwide follow-up study of new users in New Zealand. Respirology. 2017;23:583–592.
   PubMed Web of Science ®Google Scholar
• Nolan F. Census snapshot: Māori (key statistics - article, April 2002, p9). 2002. Available from: http://infoshare.stats.govt.nz/browse_for_stats/people_and_communities/maori/census-snapshot-maori.aspx#gsc.tab=0. Accessed November 12, 2020.
   Google Scholar
• Telfar Barnard L, Zhang J. The impact of respiratory disease in New Zealand: 2018 update. Asthma Respir Foundation NZ. 2019. Available from: https://www.asthmafoundation.org.nz/assets/images/NZ-Impact-Report-2018_FINAL.pdf. Accessed April 20, 2021.
   Google Scholar
• Shirtcliffe P, Weatherall M, Marsh S, et al. COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007;30(2):232–239.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Kendall C, Gamble GD, et al. Are New Zealand Māori more susceptible to smoking related lung cancer? A comparative case-case study. EC Pulmonol Respir Med. 2019;8.1:72–91.
   Google Scholar
• Stokes T, Tumilty E, Latu ATF, et al. Improving access to health care for people with severe chronic obstructive pulmonary disease (COPD) in Southern New Zealand: qualitative study of the views of health professional stakeholders and patients. BMJ Open. 2019;9(11):e033524.
   PubMed Web of Science ®Google Scholar
• NPS Medicinewise. Characterization of patients with chronic obstructive pulmonary disease (COPD) treated with single-inhaler triple therapy (SITT) or multiple-inhaler triple therapy (MITT) in Australia, using MedicineInsight and Pharmaceutical Benefits Scheme (PBS) data. 2021. Available from: https://www.nps.org.au/assets/NPS/pdf/Summary-of-GSK-COPD-project.pdf. Accessed March 29, 2021.
   Google Scholar